Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr809 Activators

Olfr809 belongs to the olfactory receptor family, a group of G protein-coupled receptors (GPCRs) crucial for the detection and transduction of odorant signals. These receptors, including Olfr809, play a pivotal role in the olfactory system, responsible for initiating the olfactory signal transduction pathway. The activation of olfactory receptors generally involves the binding of specific odorant molecules, leading to conformational changes in the receptor. These changes facilitate interaction with G proteins, triggering a series of intracellular signaling events that translate the chemical signal into a neuronal response. The specific ligands and broader physiological roles of Olfr809, as with many olfactory receptors, are not fully characterized, reflecting the complexity and diversity of olfactory receptor functions. The activation mechanisms of Olfr809, similar to other GPCRs, are modulated by various cellular factors. One significant regulatory pathway in GPCR function is the cyclic adenosine monophosphate (cAMP) signaling pathway. cAMP serves as a secondary messenger within cells and regulates a wide array of cellular functions, including GPCR signaling. The synthesis of cAMP is catalyzed by adenylate cyclase, which converts ATP into cAMP in response to external stimuli. The resulting cAMP activates protein kinase A (PKA), leading to phosphorylation of target proteins, including GPCRs. This phosphorylation can affect the receptor's sensitivity to ligands and overall responsiveness. Moreover, cAMP can interact with other signaling pathways that intersect with GPCR signaling, thereby influencing the activity of receptors such as Olfr809.

Phosphodiesterases (PDEs), responsible for the degradation of cAMP, play a crucial role in regulating its intracellular levels. Inhibiting PDEs can lead to increased cAMP levels within the cell, indirectly affecting GPCR signaling. This elevation in cAMP, due to PDE inhibition, can indirectly modulate the activity of Olfr809 through various mechanisms, such as changes in receptor phosphorylation, ligand-receptor interactions, and receptor-G protein coupling. Additionally, compounds that directly increase cAMP levels, such as adenylate cyclase activators or β-adrenergic receptor agonists, can also indirectly affect the activity of Olfr809. These interactions demonstrate the complexity of GPCR regulation and highlight the potential of various chemical compounds to modulate the activity of receptors like Olfr809 indirectly. In conclusion, understanding the activation of Olfr809 is essential for comprehending the olfactory system and the broader role of GPCRs in sensory perception and physiological processes. The complex interplay between different cellular components and signaling molecules, along with the potential for modulation by external compounds, emphasizes the complexity and significance of these receptors in sensory perception and cellular communication.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Isoproterenol Hydrochloride

51-30-9sc-202188
sc-202188A
100 mg
500 mg
$28.00
$38.00
5
(0)

Isoproterenol, a β-adrenergic agonist, elevates intracellular cAMP via adenylate cyclase activation. Increased cAMP could indirectly modulate Olfr809 signaling pathways, enhancing receptor activation and signal transduction.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

3-Isobutyl-1-methylxanthine (IBMX), a non-selective phosphodiesterase inhibitor, raises cAMP and cGMP levels, potentially influencing Olfr809 indirectly by modulating GPCR signaling pathways, altering receptor dynamics, and enhancing signaling efficacy.

(−)-Epinephrine

51-43-4sc-205674
sc-205674A
sc-205674B
sc-205674C
sc-205674D
1 g
5 g
10 g
100 g
1 kg
$41.00
$104.00
$201.00
$1774.00
$16500.00
(1)

Epinephrine, an endogenous catecholamine, stimulates α and β-adrenergic receptors, increasing cAMP via adenylate cyclase. This surge in cAMP could indirectly affect Olfr809 activation, potentially enhancing its activity through downstream signaling cascades.

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$77.00
$216.00
18
(1)

Rolipram, a phosphodiesterase 4 (PDE4) inhibitor, boosts cAMP levels. Elevated cAMP may enhance Olfr809 activity by modulating intersecting GPCR signaling pathways, altering receptor dynamics, and impacting downstream signaling.

Cilostamide (OPC 3689)

68550-75-4sc-201180
sc-201180A
5 mg
25 mg
$92.00
$357.00
16
(1)

Cilostamide, a selective PDE3 inhibitor, increases intracellular cAMP, potentially influencing Olfr809 activation by affecting GPCR-mediated signaling pathways, possibly through changes in receptor trafficking or signaling efficiency.

Salbutamol

18559-94-9sc-253527
sc-253527A
25 mg
50 mg
$94.00
$141.00
(1)

Salbutamol, a β2-adrenergic agonist, raises cAMP levels via adenylate cyclase activation. This rise might boost Olfr809 activity by impacting GPCR-linked pathways, potentially enhancing receptor activation and signal transduction.

Theophylline

58-55-9sc-202835
sc-202835A
sc-202835B
5 g
25 g
100 g
$20.00
$32.00
$85.00
6
(0)

Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP and cGMP levels. Elevated cAMP might stimulate Olfr809 by influencing associated GPCR signaling pathways, potentially affecting receptor conformation and signaling.

Dobutamine

34368-04-2sc-507555
100 mg
$295.00
(0)

Dobutamine, a synthetic catecholamine, targets β1-adrenergic receptors, increasing cAMP. This elevation could modulate Olfr809 activity by affecting GPCR-mediated signaling pathways, leading to changes in receptor activation dynamics.

Milrinone

78415-72-2sc-201193
sc-201193A
10 mg
50 mg
$165.00
$697.00
7
(0)

Milrinone, a selective PDE3 inhibitor, enhances cAMP levels, potentially influencing Olfr809 activation by affecting related GPCR signaling pathways, modifying receptor responsiveness and signaling efficacy.